2025 Rank

Total cost

Top 50 high-cost Injectable drugs

Every year, we share the top injectable drugs in an effort to provide meaningful market and data trends. Here's our compilation of the top 50 injectable drugs to help you anticipate what drugs could impact your claims. Click on each injectable drug name below to view year-over-year member data and learn more about each drug!

Keytruda

$93.0M

Opdivo

$27.9M

Darzalex Faspro

$33.5M

Tepezza

$10.7M

Ultomiris

$16.4M

Perjeta

$15.1M

Adcetris

$9.6M

Neulasta

$10.6M

Yervoy

$13.1M

Enhertu

$22.2M

Average cost

# of users

603

239

201

159

381

104

124

$178.8K

$125.5K

$27.8K

$253.2K

$95.2K

$409.1K

$305.1K

$166.7K

$116.9K

$154.3K

Cancer

Blood Disorder

All others

RESET

Click here to filter by category

Soliris

$5.3M

$332.1K

Ocrevus

104

$11.2M

$107.3K

Krystexxa

$10.2M

$441.7K

Kadcyla

$10.6M

$142.8K

Kyprolis

$4.5M

$94.9K

Uncategorized Drugs

1497

$8.99M

$6K

Gamunex-C, Gammaked

116

$7.7M

$66.7K

Durvalumab

$11.4M

$119.9K

Hemlibra

$9.5M

$431.7K

Gammagard

106

$6.7M

$63.1K

Padcev

$7.2M

$257.0K

Romiplostim

$7.2M

$135.8K

Blincyto

$9.7M

$268.9K

Zolgensma

$7.3M

$1.8M

Opdualag

$8.2M

$356.4K

Rylaze

$7.1M

$506.1K

Trodelvy

$8.9M

$181.2K

Spinraza

$4.4M

$403.8K

Herceptin

$5.9M

$98.5K

Lumizyme, Myozyme

$10.1M

$1M

Vyvgart

$8.6M

$408.4K

Vectibix

$4.7M

$119.9K

Tecentriq

$4.9M

$113.7K

Xgeva

251

$4.8M

$19.2K

Entyvio

$5.9M

$74.1K

Privigen

$5.2M

$83.3K

Kimmtrak

$4.8M

$1.19M

Viltepso

$6.2M

$1M

Nplate

$4.5M

$112.1K

Phesgo

$5.0M

$96.7K

Abraxane

$4.2M

$59.6K

Inflectra, Remicase

$4.2M

$58.8K

Nexviazyme

$4.2M

$601.5K

Rybrevant

$4.2M

$385.9K

Hemgenix

$3.5M

Polivy (Polatuzumab vedotin-piiq)

$4.0M

$143.8K

Skyrizi (Risankizumab-rzaa)

$4.0M

$42.7K

Cyramza

$3.9M

$123.2K

Alprolix

$3.7M

$739.2K

Source: Sun Life book of business data. Top 20 rank order, average paid, total paid and condition category are all based on 2024 book of business data. Group stop-loss insurance policies are underwritten by Sun Life Assurance Company of Canada (Wellesley Hills, MA) in all states, except New York, under Policy Form Series 07-SL REV 7-12 and 22-SL. In New York, Group stop-loss insurance policies are underwritten by Sun Life and Health Insurance Company (U.S.) (Lansing, MI) under Policy Form Series 07-NYSL REV 7-12 and 22-NYSL. Policy offerings may not be available in all states and may vary due to state laws and regulations. Not approved for use in New Mexico. © 2026 Sun Life Assurance Company of Canada, Wellesley Hills, MA 02481. All rights reserved. The Sun Life name and logo are registered trademarks of Sun Life Assurance Company of Canada. Visit us at www.sunlife.com/us. SLDX-1573-3-b #1362359261 05/24 (exp. 05/26)

Asparlas (Calaspargase Pegol)

$4.3M

$155.1K

Injectable drugs for cancer

Injectable Drug

Total Cost

# of Users

Average Cost

Injectable Drug

Total Cost

# of Users

Average Cost

Injectable drugs for blood disorders

Injectable drugs for all other categories

Injectable drug

2025 Rank

Click on each injectable drug name below to learn more!

2025 Rank

Injectable drug

# of users

Total cost

Average cost

Keytruda

603

$93M

$154.3K

Darzalex Faspro

201

$33.5M

$166.7K

Opdivo

239

$27.9M

$116.9K

Enhertu

124

$22.2M

$178.8K

Perjeta

159

$15.1M

$$95.2K

Yervoy

104

$13.1M

$125.5K

Durvalumab

$11.4M

$119.9K

Neulasta

381

$10.6M

$$27.8K

Kadcyla

$10.6M

$142.8K

Blincyto

$9.7M

$268.9K

Adcetris

$9.6M

$253.2K

Trodelvy

$8.9M

$181.2K

Opdualag

$8.2M

$356.4K

Padcev

$7.2M

$257.0K

Rylaze

$7.1M

$506.1K

Phesgo

$5M

$96.7K

Tecentriq

$4.9M

$113.7K

Xgeva

251

$4.8M

$19.2K

Kimmtrak

$4.8M

$1.2M

Jemperli (Dostarlimab-gxly)

$4.8M

198.7K

Vectibix

$4.7M

$119.9K

Kyprolis

$4.5M

$94.9K

Asparlas (Calaspargase Pegol)

$4.3M

$155.1K

Rybrevant

$4.2M

$385.9K

Polivy (Polatuzumab vedotin-piiq)

$4M

$143.8K

Cyramza

$3.9M

$123.2K

Ultomiris

$16.4M

$409.1K

Hemlibra

$9.5M

$431.7K

Soliris

$5.3M

$332.1K

Romiplostim

$7.2M

$135.8K

Advate, Kogenate

$3.6M

$241.9K

Elevidys

$12.9M

$3.2M

Tepezza

$10.7M

$305.1K

Krystexxa

$10.2M

$441.7K

Lumizyme, Myozyme

$10.1M

$1M

Vyvgart

$8.6M

$408.45K

Zolgensma

$7.3M

$1.8M

Viltepso

$6.2M

$1.05M

Zynteglo

$5.6M

$2.8M

Privigen

$5.2M

$83.3K

Vyvgart Hytrulo

$4.6M

$270.4K

Nplate

$4.5M

$112.1K

Spinraza

$4.4M

$403.8K

Nexviazyme

$4.2M

$601.5K

Crysvita

$4.1M

$413.9K

Skyrizi (Risankizumab-rzaa)

$4M

$42.7K

Alprolix

$3.7M

$739.2K

Hemgenix

$3.5M

Brineura

$3.17M

Somatuline Depot

$3.16M

$98.9K

Elevidys

$12.9M

$3.22M

Zynteglo

$5.6M

$2.8M

Jemperli (Dostarlimab-gxly)

$4.8M

$198.7K

Vygart Hytrulo

$4.6M

$270.4K

Crysvita

$4.1M

$413.9K

Keytruda

Interferes with the growth and spread of cancer cells in the body. Used in adults and some children with certain advanced forms of cancer.

Primarily used in the treatment of:

Cancer

Total cost:

$154.3K

fda approval year:

2014

2025

2024

Injectable drug rank

#1

Average cost

$93.0M

Increase in member count from 2022 to 2025

90%

Member Count Year over Year

Darzalex Faspro

Monoclonal antibody that blocks a specific protein in the body that affects tumor growth. Used to treat multiple myeloma in adults. Faspro is a combination of the original Darzalex and hyaluronidase and is administered under the skin in the abdomen as opposed to the original drug being administered through an IV.

Primarily used in the treatment of:

Cancer

Total cost:

$166.7K

2020

2025

2024

Injectable drug rank

#2

#3

Average cost:

$33.5M

fda approval year:

Increase in member count from 2022 to 2025

70%

Member Count Year over Year

Opdivo

Used alone or in combination of other drugs that work with a person’s immune system to inhibit the growth and spread of cancer cells in the body.

Primarily used in the treatment of:

Cancer

Total cost:

$116.9K

2025

2024

Injectable drug rank

#3

#2

Average cost:

$27.9M

Increase in member count from 2022 to 2025

30%

2014

fda approval year:

Member Count Year over Year

Enhertu

A chemotherapy drug that is used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$178.8K

fda approval year:

2019

2025

2024

Injectable drug rank

#4

#10

Average cost:

$22.2M

Increase in member count from 2022 to 2025

310%

Ultomiris

Monoclonal antibody that treats paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic disorder in which defective red blood cells break down prematurely and leak hemoglobin into your blood.

Primarily used in the treatment of:

Blood Disorder

Member Count Year over Year

Total cost:

$409.1K

2024

2023

Injectable drug rank

#5

Average cost:

$16.4M

Increase in member count from 2022 to 2025

150%

fda approval year:

2018

Perjeta

Interferes with the growth and spread of cancer cells in the body. Used in combination with other medications to treat HER2-positive breast cancer.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$95.2K

2024

2023

Injectable drug rank

#6

Average cost:

$15.1M

growth in member count from 2022 to 2025

10%

2012

fda approval year:

Yervoy

Used in combination with other medicines in the treatment of certain types of cancer like: skin, lung, kidney, liver among others.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$125.5K

2025

2024

Injectable drug rank

#7

#9

Average cost:

$13.1M

Increase in member count from 2022 to 2025

60%

2011

fda approval year:

Elevidys

A one-time gene therapy used to treat children and adults with Duchenne muscular dystrophy who are still able to walk. It delivers a specialized gene to muscle cells to help slow down muscle loss and disease progression.

Primarily used in the treatment of:

OTHER

Member Count Year over Year

Total cost:

$3.2M

2025

2024

Injectable drug rank

#8

N/A

Average cost:

$12.9M

Increase in member count from 2022 to 2025

N/A

2023

fda approval year:

Durvalumab

An immunotherapy used to treat cancer of the lungs, bladder, or urinary tract.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$119.9K

fda approval year:

2017

2025

2024

Injectable drug rank

#9

#18

Average cost:

$11.4M

Increase in member count from 2022 to 2025

150%

Ocrevus

Used to treat primary progressive multiple sclerosis and relapsing forms of multiple sclerosis in adults.

Primarily used in the treatment of:

IMMUNODEFICIENCY

Member Count Year over Year

Total cost:

$107.3K

2025

2024

Injectable drug rank

#10

#12

Average cost:

$11.2M

Increase in member count from 2022 to 2025

20%

2017

fda approval year:

Tepezza

An insulin-like growth factor-1 receptor inhibitor (IGF-IR) used to treat thyroid eye disease.

Primarily used in the treatment of:

Thyroid eye Disease

Total cost:

$305.1K

2025

2024

Injectable drug rank

#11

#4

Average cost:

2020

fda approval year:

Decrease in member count from 2022 to 2025

-10%

Member Count Year over Year

$10.7M

Neulasta

Used to stimulate growth of white blood cells in the body to help fight against infection for people receiving chemotherapy and radiation therapy.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$27.8K

2025

2024

Injectable drug rank

#12

#8

Average cost:

$10.6M

Decrease in member count from 2022 to 2025

-0%

2002

fda approval year:

Kadcyla

Interferes with the growth and spread of cancer cells in the body. Used in the treatment of breast cancer both early and those that have spread to other parts of the body (metastatic).

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$142.8K

2025

2024

Injectable drug rank

#13

#14

Average cost:

$10.6M

Increase in member count from 2022 to 2025

50%

2013

fda approval year:

Krystexxa

An enzyme that metabolizes uric acid into a harmless chemical that is eliminated from the body in urine. Used in adults to help reduce the signs and symptoms of gout that are not controlled by other treatments.

Primarily used in the treatment of:

Gout

Member Count Year over Year

Total cost:

$441.7K

2025

2024

Injectable drug rank

#14

#13

Average cost:

$10.2M

Increase in member count from 2022 to 2025

230%

fda approval year:

2010

Lumizyme, Myozyme

Contains an enzyme that naturally occurs in the body. Some people lack this enzyme due to a genetic disorder. Used to treat a glycogen storage disorder called Pompe disease, (also called GAA deficiency) in adults and children.

Primarily used in the treatment of:

Genetic disorder

Member Count Year over Year

Total cost:

$1.0M

fda approval year:

2010

2025

2024

Injectable drug rank

#15

#30

Average cost:

$10.1M

Increase in member count from 2022 to 2025

30%

Blincyto

Used to treat a certain type of acute lymphoblastic leukemia in adults and children, when other cancer treatments have been unsuccessful.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$268.9K

fda approval year:

2014

2025

2024

Injectable drug rank

#16

#23

Average cost:

$9.7M

Increase in member count from 2022 to 2025

200%

Adcetris

Interferes with the growth and spread of cancer cells in the body. Used to treat classical Hodgkin lymphoma that could relapse or has already relapsed after a stem cell transplant.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$253.2K

2025

2024

Injectable drug rank

#17

#7

Average cost:

$9.6M

Decrease in member count from 2022 to 2025

0%

2011

fda approval year:

Hemlibra

Monoclonal antibody that treats hemophilia by functioning in place of natural blood-clotting factor that is missing in people with Hemophilia A.

Primarily used in the treatment of:

Blood Disorders

Member Count Year over Year

Total cost:

$431.7K

2025

2024

Injectable drug rank

#18

#19

Average cost:

$9.5M

Increase in member count from 2022 to 2025

60%

2018

fda approval year:

Trodelvy

An antibody-drug conjugate immune targeted therapy that is used to treat certain types of breast, bladder, and urinary tract cancers.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$181.2K

fda approval year:

2020

2025

2024

Injectable drug rank

#19

#27

Average cost:

$8.9M

Increase in member count from 2022 to 2025

150%

Vyvgart

Approved for use for Myasthenia gravis 9MG, a chronic autoimmune disorder where antibodies destroy communication between nerves and muscles, resulting in muscle weakness.

Primarily used in the treatment of:

Myasthenia gravis

Member Count Year over Year

Total cost:

$408.4K

2025

2024

Injectable drug rank

#20

#31

Average cost:

$8.6M

Increase in member count from 2022 to 2025

600%

fda approval year:

2023

Opdualag

Approved for treating patients 12 and over with unresectable or metastatic melanoma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$356.4K

fda approval year:

2022

2025

2024

Injectable drug rank

#21

#25

Average cost:

$8.2M

Increase in member count from 2023 to 2025

190%

Gamunex-C, Gammaked

Used to treat primary immunodeficiency in adults and children over two years old. Also used for immune thrombocytopenic purpura (ITP) and as bacterial infection prophylaxis.

Primarily used in the treatment of:

Immunodificiency

Member Count Year over Year

Total cost:

$66.7K

fda approval year:

2003

2025

2024

Injectable drug rank

#22

#17

Average cost:

$7.7M

Increase in member count from 2022 to 2025

80%

Zolgensma

Gene therapy used for spinal muscular atrophy (SMA). Provides children under 2 with a new functional or working copy of a human SMA gene.

Primarily used in the treatment of:

GENETIC DISORDER

Member Count Year over Year

Total cost:

$1.8M

fda approval year:

2019

2025

2024

Injectable drug rank

#23

#24

Average cost:

$7.3M

Increase in member count from 2022 to 2025

30%

Padcev

Originally approved to treat patients who would not receive certain chemotherapies, Padcev’s approval was expanded to treat patients with metastatic urothelial cancer in 2023.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$257.0K

2025

2024

Injectable drug rank

#24

#21

Average cost:

$7.2M

Increase in member count from 2022 to 2025

300%

2019

fda approval year:

Rylaze

Used to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adults and children at least 1 month old who have become allergic to other forms of asparaginase such as Elspar, Oncaspar or Erwinase.

$506.1K

Average cost:

2024

#26

2025

#25

Injectable drug rank

Total cost:

$7.1M

Primarily used in the treatment of:

Cancer

Member Count Year over Year

fda approval year:

2021

Increase in member count from 2022 to 2025

80%

Gammagard

Used to treat primary immunodeficiency in adults and children over two years old. Also used to treat immune thrombocytopenic purpura (ITP) and bacterial infection prophylaxis.

Primarily used in the treatment of:

Immunodeficiency

Member Count Year over Year

Total cost:

$63.1K

2025

2024

Injectable drug rank

#26

#20

Average cost:

$6.7M

Increase in member count from 2022 to 2025

30%

fda approval year:

2005

Viltepso

Second drug granted FDA approval in the treatment of Duchenne muscular dystrophy, one of the most severe forms of inherited muscular dystrophies.

Primarily used in the treatment of:

Duchenne muscular dystrophy

Member Count Year over Year

Total cost:

$1.0M

2025

2024

Injectable drug rank

#27

#38

Average cost:

$6.2M

Increase in member count from 2022 to 2025

500%

fda approval year:

2020

Entyvio

Reduces the effects of a substance in the body that can cause inflammation. Used in adults with moderate to severe ulcerative colitis (UC), or moderate to severe Crohn disease.

Primarily used in the treatment of:

IMMUNODEFICIENCY

Member Count Year over Year

Total cost:

$74.1K

fda approval year:

2014

2025

2024

Injectable drug rank

#28

#35

Average cost:

$5.9M

Increase in member count from 2022 to 2025

10%

Zynteglo

A one-time gene therapy that uses a patient’s own modified stem cells to help them produce healthy red blood cells and eliminate the need for regular transfusions.

Primarily used in the treatment of:

beta-thalassemia (gene therapy)

Member Count Year over Year

Total cost:

$2.8M

2025

2024

Injectable drug rank

#29

#N/A

Average cost:

$5.6M

Increase in member count from 2022 to 2025

N/A

fda approval year:

2022

Soliris

Monoclonal antibody that binds proteins in the blood that destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells. Also treats certain neurological disorders.

Primarily used in the treatment of:

Blood Disorder

Member Count Year over Year

Total cost:

$332.1K

2025

2024

Injectable drug rank

#30

#11

Average cost:

$5.3M

Decrease in member count from 2022 to 2025

-40%

2007

fda approval year:

Privigen

Used to treat primary immunodeficiency in adults and children over two years old. Also used for immune thrombocytopenic purpura (ITP) and as bacterial infection prophylaxis.

Primarily used in the treatment of:

Immunodeficiency

Member Count Year over Year

Total cost:

$83.3K

fda approval year:

2007

2025

2024

Injectable drug rank

#31

#36

Average cost:

$5.2M

Increase in member count from 2022 to 2025

40%

Phesgo

Used primarily in the treatment of HER2 positive breast cancer. It’s a combination of 3 other drugs that is given via IV injection

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$96.7K

fda approval year:

2020

2025

2024

Injectable drug rank

#32

#40

Average cost:

$5.0M

Increase in member count from 2022 to 2025

330%

Tecentriq

Monoclonal antibody that strengthens the immune system to help fight against tumor cells. Used to treat certain cancers like bladder, lung, breast, liver, and skin.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$113.7K

2025

2024

Injectable drug rank

#33

Average cost:

$4.9M

Decrease in member count from 2022 to 2025

0%

fda approval year:

2016

Xgeva

Monoclonal antibody used to prevent bone fractures and other skeletal conditions in people with multiple myeloma, and in people with tumors that have spread to the bone.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$19.2K

fda approval year:

2010

2025

2024

Injectable drug rank

#34

Average cost:

$4.8M

Increase in member count from 2022 to 2025

20%

Kimmtrak

Approved for treating patients with unresectable or metastatic uveal melanoma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$1.18M

fda approval year:

2022

2025

2024

Injectable drug rank

#35

#37

Average cost:

$4.8M

Decrease in member count from 2023 to 2025

-20%

Jemperli (Dostarlimab-gxly)

An immunotherapy used to treat adults with certain types of advanced or recurrent cancers that have specific genetic features known as dMMR (mismatch repair-deficient).

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$198.7K

fda approval year:

2021

2025

2024

Injectable drug rank

#36

#55

Average cost:

$4.8M

Increase in member count from 2024 to 2025

60%

Vectibix

Used in the treatment of metastatic colorectal carcinoma. Vectibix has been granted expanded use cases since its FDA approval, notably in 2014 and 2017.

Primarily used in the treatment of:

cancer

Member Count Year over Year

Total cost:

$119.9K

2025

2024

Injectable drug rank

#37

#32

Average cost:

$4.7M

Increase in member count from 2022 to 2025

90%

fda approval year:

2006

Vyvgart Hytrulo

A prescription medicine used to treat adults with certain autoimmune conditions by reducing harmful antibodies in the body.

Primarily used in the treatment of:

Myasthenia Gravis

Member Count Year over Year

Total cost:

$270.4K

2025

2024

Injectable drug rank

#38

N/A

Average cost:

$4.6M

Increase in member count

N/A

fda approval year:

2023

Nplate

A prescription medicine used to increase platelet counts in adults and children with immune thrombocytopenia (ITP) to help prevent bleeding.

Primarily used in the treatment of:

Thrombocytopenia

Member Count Year over Year

Total cost:

$112.1K

2025

2024

Injectable drug rank

#39

#N/A

Average cost:

$4.5M

Increase in member count

N/A

fda approval year:

2008

Kyprolis

Interferes with the growth and spread of cancer cells. Used to treat multiple myeloma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$94.9K

fda approval year:

2012

2025

2024

Injectable drug rank

#40

#15

Average cost:

$4.5M

Increase in member count from 2022 to 2025

10%

Spinraza

Helps the body produce an essential protein for the function of nerves that control muscle movement. Used to treat spinal muscular atrophy in adults, children, and infants.

Primarily used in the treatment of:

Genetic Disorder

Member Count Year over Year

Total cost:

$403.8K

2025

2024

Injectable drug rank

#41

#28

Average cost:

$4.4M

Decrease in member count from 2022 to 2025

-30%

fda approval year:

2016

Asparlas (Calaspargase Pegol)

Primarily used in the treatment of:

Acute lymphoblastic leukemia

Member Count Year over Year

Total cost:

$155.1K

fda approval year:

2018

2025

2024

Injectable drug rank

#42

#50

Average cost:

$4.3M

Approved to treat patients age 1 month to 21 years with acute lymphoblastic leukemia (ALL).

250%

Increase in member count from 2023 to 2025

Rybrevant

Primarily used in the treatment of:

Non–small cell lung cancer, locally advanced or metastatic

Member Count Year over Year

Total cost:

$385.9K

fda approval year:

2021

2025

2024

Injectable drug rank

#43

#253

Average cost:

$4.2M

A targeted therapy used to treat adults with advanced non-small cell lung cancer that has specific genetic mutations (EGFR).

1000%

Increase in member count from 2024 to 2025

Nexviazyme

Primarily used in the treatment of:

Pompe Disease

Member Count Year over Year

Total cost:

$601.5K

fda approval year:

2021

2025

2024

Injectable drug rank

#44

#43

Average cost:

$4.2M

Increase in member count from 2023 to 2025

250%

Approved to treat patients one year and older with late onset Pompe disease, a disease that causes weakened muscles that can lead to heart failure or respiratory failure.

Crysvita

Primarily used in the treatment of:

X-linked hypophosphatemia

Member Count Year over Year

Total cost:

$413.9K

fda approval year:

2018

2025

2024

Injectable drug rank

#45

#52

Average cost:

$4.1M

Prescription medication used to treat certain rare conditions that cause low phosphate levels in the blood.

42%

Increase in member count from 2024 to 2025

Polivy (Polatuzumab vedotin-piiq)

Primarily used in the treatment of:

Diffuse large B-cell lymphoma

Member Count Year over Year

Total cost:

$143.8K

fda approval year:

2019

2025

2024

Injectable drug rank

#46

#60

Average cost:

$4.0M

An antibody-drug conjugate used to treat adults with certain types of non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma (DLBCL).

47%

Increase in member count from 2024 to 2025

Skyrizi (Risankizumab-rzaa)

Primarily used in the treatment of:

Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

Member Count Year over Year

Total cost:

$42.7K

fda approval year:

2018

2025

2024

Injectable drug rank

#47

#79

Average cost:

$4.0M

Approved to treat patients age 1 month to 21 years with acute lymphoblastic leukemia (ALL).

111%

Increase in member count from 2024 to 2025

Cyramza

Interferes with the growth and spread of cancer cells in the body. Used to treat stomach cancer, colorectal cancer, or non-small cell lung cancer that has spread to other parts of the body, and hepatocellular carcinoma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$123.2K

fda approval year:

2014

2025

2024

Injectable drug rank

#48

#61

Average cost:

$3.9M

Increase in member count from 2024 to 2025

68%

Alprolix

Primarily used in the treatment of:

Blood-clotting disorder

Member Count Year over Year

Total cost:

$739.2K

fda approval year:

2014

2025

2024

Injectable drug rank

#49

#58

Average cost:

$3.7M

Used to prevent or control bleeding episodes in adults and children who have hemophilia B, a genetic condition where the body doesn't produce enough clotting factor IX.

0%

Increase in member count from 2024 to 2025

Hemgenix

Primarily used in the treatment of:

Hemophilia B

Member Count Year over Year

Total cost:

$3.5M

fda approval year:

2022

2025

2024

Injectable drug rank

#50

#45

Average cost:

$3.5M

Used to treat hemophilia B in adults who currently use Factor IX prophylaxis therapy, or who have current or historical life-threatening bleeding, or who have repeated, serious spontaneous bleeding episodes.

0%

Increase in member count from 2024 to 2025

ROMIPLOSTIM

Used to increase the number of platelets (cells that help the blood to clot) in order to decrease the risk of bleeding in adults with a blood disorder called immune thrombocytopenia.

Primarily used in the treatment of:

BLOOD DISORDER

Member Count Year over Year

Total cost:

$135.8K

fda approval year:

2018

2024

2023

Injectable drug rank

#22

#13

Average cost:

$7.2M

Increase in member count from 2021 to 2024

170%

Uncategorized Drugs

Refers to several drugs that are new, have not yet been assigned a unique J-Code or drug class. These drugs may receive their own J-Code over time.

$5.9K

Average cost:

2023

#68

2024

#16

Injectable drug rank

Total cost:

$8.97M

Primarily used in the treatment of:

Varies

Member Count Year over Year

fda approval year:

VARIES

Increase in member count from 2023 to 2024

50%

Fabrazyme

A man-made form of the naturally occurring alpha-galactosidase. Used to treat Fabry disease in adults and on children over 2 years old.

Primarily used in the treatment of:

Genetic Disorder

Member Count Year over Year

Total cost:

$357.2K

2024

2023

Injectable drug rank

#47

#21

Average cost:

$3.2M

Decrease in member count from 2021 to 2024

-10%

fda approval year:

2003

Advate, Kogenate

Helps prevent and control bleeding episodes in children and adults with Hemophilia A.

Primarily used in the treatment of:

Blood Disorder

Member Count Year over Year

Total cost:

$241.96K

2024

2023

Injectable drug rank

#44

#25

Average cost:

$3.6M

Decrease in member count from 2021 to 2024

-29%

fda approval year:

2003

Inflectra, Remicade

A tumor necrosis factor (TNF) alfa inhibitor used to treat Chron disease in adults and children under six. Also, treats certain types of arthritis.

Primarily used in the treatment of:

Chronic Inflamatory Diseases

Member Count Year over Year

Total cost:

$58.8K

2024

2023

Injectable drug rank

#42

#29

Average cost:

$4.17M

Decrease in member count from 2021 to 2024

-27%

Biosimilars approved 2016-2019

fda approval year:

1998

Erbitux

Interferes with the growth and spread of cancer cells in the body. Used to treat cancers of the colon and rectum. It is also used to treat head and neck cancer.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$168.8K

fda approval year:

2004

2024

2023

Injectable drug rank

#39

#30

Average cost:

$4.56M

Increase in member count from 2021 to 2024

17%

Herceptin

Used to interfere with the growth and spread of cancer cells in the body in the treatment of breast or stomach cancer.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$98.5K

2024

2023

Injectable drug rank

#29

#32

Average cost:

$5.9M

Decrease in member count from 2021 to 2024

-47%

1998

fda approval year:

Somatuline Depot

A man-made protein similar to a hormone in the body called somatostatin. Used to treat acromegaly that cannot be treated with surgey or radiation, carcinoid syndrom, or a certain type of pancreatic or digestic tract tumor.

Primarily used in the treatment of:

Acromegaly

Member Count Year over Year

Total cost:

$98.8K

2024

2023

Injectable drug rank

#49

#40

Average cost:

$3.16M

Increase in member count from 2021 to 2024

10%

fda approval year:

2007

Abraxane

Interferes with the growth and spread of cancer cells. Used to treat advanced breast, lung or pancreatic cancers.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$59.6K

fda approval year:

2005

2024

2023

Injectable drug rank

#41

Average cost:

$4.2M

Decrease in member count from 2021 to 2024

-21%

Avastin

Used to interfere with the growth and spread of cancer cells in the body in the treatment of a certain type of brain tumor, and other cancers like kidney, liver, lung, colon, rectum, cervix, ovary, or fallopian tube.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$28.9K

2024

2023

Injectable drug rank

#46

#42

Average cost:

$3.3M

Decrease in member count from 2021 to 2024

-30%

fda approval year:

2004

Brineura

First drug granted FDA approval in the treatment of Batten’s disease. This treatment slows the loss of walking ability in patients age 3 and up.

Primarily used in the treatment of:

neuronal ceroid lipofuscinoses

Member Count Year over Year

Total cost:

$3.18M

2024

2023

Injectable drug rank

#48

#46

Average cost:

$3.18M

Change in member count from 2022 to 2024

0%

fda approval year:

2017

Givlaari

A medication used to treat acure hepatic porphyria in adults. It is a small interfering RNA directed towards an important enzyme in the production of heme.

Primarily used in the treatment of:

Genetic disorder

Member Count Year over Year

Total cost:

$1.2M

fda approval year:

2019

2022

2021

Injectable drug rank

#44

#0

Average cost:

$2.4M

Alimta

Interferes in the growth and spread of cancer cells. Used in the treatment of certain types of lung cancers.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$52.9K

2023

2022

Injectable drug rank

#35

#19

Average cost:

$3.8M

Decrease in member count from 2020 to 2023

-10%

fda approval year:

2004

Tysabri

Monoclonal antibody that affects the actions of the body's immune system. Used to treat relapsing forms of multiple sclerosis and moderate to severe Crohn disease in adults.

Primarily used in the treatment of:

Monoclonal antibody

Member Count Year over Year

Total cost:

$95.3K

fda approval year:

2004

2023

2022

Injectable drug rank

#43

#38

Average cost:

$3M

Increase in member count from 2020 to 2023

10%

Vyondys 53

Used in the treatment of Duchenne Muscular Dystrophy, specifically for patients with a genetic mutation on a specific gene.

Primarily used in the treatment of:

Duchenne muscular dystrophy

Member Count Year over Year

Total cost:

$943.2K

2023

Injectable drug rank

#44

N/A

Average cost:

$2.8M

Increase in member count from 2021 to 2023

50%

fda approval year:

2019

Truxima

Can be used alone or in combination with other medicines to treat Rheumatoid arthritis and non-Hodgkin lymphoma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$54.6K

fda approval year:

2018

2023

2022

Injectable drug rank

#45

#32

Average cost:

$2.7M

Decrease in member count from 2020 to 2023

-70%

Poteligeo

Treats rare and difficult to treat forms of non-hodgkins lymphoma, called Mycosis fungoides (MF) and Sezay Syndrome (SS).

Primarily used in the treatment of:

Mycosis fungoides, relapsed or refractory

Member Count Year over Year

Total cost:

$457.1K

2023

2022

Injectable drug rank

#48

N/A

Average cost:

$2.3M

Increase in member count from 2021 to 2023

400%

fda approval year:

2018

Octagam

Contains antibodies to help your body protect itself against infection. Used to treat primary humoral immunodeficiency (PI), immune thrombocytopenic purpura (ITP) and dermatomyositis (DM).

Primarily used in the treatment of:

Immunodeficiency

Member Count Year over Year

Total cost:

$65.9K

fda approval year:

2014

2023

2022

Injectable drug rank

#50

#39

Average cost:

$2.2M

Increase in member count from 2020 to 2023

40%

Velcade

Interferes with the growth and spread of cancer cells. Used to treat multiple myeloma and mantle cell lymphoma.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$36K

fda approval year:

2003

2022

2021

Injectable drug rank

#36

Average cost:

$3.6M

Increase in member count from 2019 to 2022

65%

Darzalex

Monoclonal antibody that targets and destroys certain cells in the body. Used in the treatment of multiple myeloma, often in combination with other drugs.

Primarily used in the treatment of:

Cancer

Member Count Year over Year

Total cost:

$120.8K

fda approval year:

2015

2022

2021

Injectable drug rank

#41

#30

Average cost:

$2.9M

Decrease in member count from 2019 to 2022

-40%

Onpattro

Prescription medication used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hereditary transthyretin-mediated amyloidosis (hATTR).

Primarily used in the treatment of:

GENETIC DISORDER

Member Count Year over Year

Total cost:

$341.6K

fda approval year:

2018

2022

2021

Injectable drug rank

#48

#49

Average cost:

$2.1M

Increase in member count from 2021 to 2022